FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2593239796> ?p ?o ?g. }

• W2593239796 abstract "Background Mutations in ESR1 , the gene encoding the estrogen receptor, have been linked to endocrine resistance in metastatic breast cancer (MBC). It is thought that these mutations are selected during endocrine treatment (ET), but direct evidence that these ESR1 mutations (m ESR1 ) emerge during treatment with endocrine agents is scant. We set out to evaluate m ESR1 in circulating tumor cells (CTCs) and matched plasma cell-free DNA (cfDNA) of MBC patients before start of 1 st line ET and at progression. Materials & Methods CellSearch-enriched CTCs (≥ 5 CTC/7.5 mL) of 37 MBC patients before start of 1 st line ET (baseline cohort; BL) and 38 MBC patients who had progressed on any line of ET for metastatic disease (progressive disease cohort; PD) were evaluated. 52% of the PD patients received one line of ET and 48% more lines, of which 92% contained an aromatase inhibitor. In addition, 10 CellSearch-enriched fractions from healthy blood donors (HBDs) and 46 matched plasma samples (7xHBD, 15xBL, 24xPD) were included. DNA was isolated using the AllPrep kit and cfDNA with the QIAamp CNA kit (Qiagen). Hotspot mutations for ESR1 (D538G, Y537S, Y537C and Y537N) were evaluated with mutation-specific Taqman assays by chip-based digital PCR (QuantStudio 3D). m ESR1 status was assessed after target-specific ESR1 amplification capturing all 4 mutations, with thresholds for positivity based on the highest variant allele frequencies in HBDs. Results Of all the CTC samples in the BL cohort, 1 patient had mutated Y537N copies, while this mutation was not detected in the matched cfDNA. This patient had received adjuvant treatment with tamoxifen. Also none of the other 14 BL cfDNA samples analyzed harbored m ESR1 . Three PD patients (8%) were positive for m ESR1 in their CTCs (2x D538G and 1x Y537S). These D538G variants identified in CTCs were also detected in the corresponding cfDNA of these patients; for the Y537S mutation no matched cfDNA was available. Seven additional m ESR1 carriers were identified in the other 22 matched cfDNA PD samples, resulting in 38% m ESR1 positivity of the PD plasma samples (7x D538G, 1x Y537C and 1x Y537C). Conclusion Sensitivity for detecting m ESR1 in CTC fractions (identified in 8% of the PD patients) was lower than for cfDNA samples. Using cfDNA for m ESR1 detection, we found an higher prevalence of m ESR1 variants in samples obtained at progression to ET (38%) compared to baseline (0%). These findings further substantiate the role of m ESR1 in endocrine resistance. Citation Format: Sieuwerts AM, Beije N, Kraan J, Van M, Onstenk W, Vitale SR, van der Vlugt – Daane M, Hamberg P, Dirix LY, Brouwers A, de Jongh FE, Jager A, Seynaeve CM, Jansen MPHM, Foekens JA, Martens JWM, Sleijfer S. ESR1 mutations in circulating tumor cell versus circulating cell-free DNA of metastatic breast cancer patients before first-line endocrine therapy and at progression [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-02-02." @default.
• W2593239796 created "2017-03-16" @default.
• W2593239796 creator A5012303801 @default.
• W2593239796 creator A5014770720 @default.
• W2593239796 creator A5019863052 @default.
• W2593239796 creator A5037339432 @default.
• W2593239796 creator A5042296203 @default.
• W2593239796 creator A5047526970 @default.
• W2593239796 creator A5047764279 @default.
• W2593239796 creator A5047837719 @default.
• W2593239796 creator A5047950538 @default.
• W2593239796 creator A5053613815 @default.
• W2593239796 creator A5064453966 @default.
• W2593239796 creator A5066253064 @default.
• W2593239796 creator A5071087901 @default.
• W2593239796 creator A5076915126 @default.
• W2593239796 creator A5077029227 @default.
• W2593239796 creator A5084137118 @default.
• W2593239796 creator A5086664857 @default.
• W2593239796 date "2017-02-14" @default.
• W2593239796 modified "2023-09-26" @default.
• W2593239796 title "Abstract P1-02-02:ESR1mutations in circulating tumor cell versus circulating cell-free DNA of metastatic breast cancer patients before first-line endocrine therapy and at progression" @default.
• W2593239796 doi "https://doi.org/10.1158/1538-7445.sabcs16-p1-02-02" @default.
• W2593239796 hasPublicationYear "2017" @default.
• W2593239796 type Work @default.
• W2593239796 sameAs 2593239796 @default.
• W2593239796 citedByCount "1" @default.
• W2593239796 countsByYear W25932397962017 @default.
• W2593239796 crossrefType "proceedings-article" @default.
• W2593239796 hasAuthorship W2593239796A5012303801 @default.
• W2593239796 hasAuthorship W2593239796A5014770720 @default.
• W2593239796 hasAuthorship W2593239796A5019863052 @default.
• W2593239796 hasAuthorship W2593239796A5037339432 @default.
• W2593239796 hasAuthorship W2593239796A5042296203 @default.
• W2593239796 hasAuthorship W2593239796A5047526970 @default.
• W2593239796 hasAuthorship W2593239796A5047764279 @default.
• W2593239796 hasAuthorship W2593239796A5047837719 @default.
• W2593239796 hasAuthorship W2593239796A5047950538 @default.
• W2593239796 hasAuthorship W2593239796A5053613815 @default.
• W2593239796 hasAuthorship W2593239796A5064453966 @default.
• W2593239796 hasAuthorship W2593239796A5066253064 @default.
• W2593239796 hasAuthorship W2593239796A5071087901 @default.
• W2593239796 hasAuthorship W2593239796A5076915126 @default.
• W2593239796 hasAuthorship W2593239796A5077029227 @default.
• W2593239796 hasAuthorship W2593239796A5084137118 @default.
• W2593239796 hasAuthorship W2593239796A5086664857 @default.
• W2593239796 hasConcept C121608353 @default.
• W2593239796 hasConcept C126322002 @default.
• W2593239796 hasConcept C143998085 @default.
• W2593239796 hasConcept C172313692 @default.
• W2593239796 hasConcept C2775930923 @default.
• W2593239796 hasConcept C2776166826 @default.
• W2593239796 hasConcept C2778504769 @default.
• W2593239796 hasConcept C2779013556 @default.
• W2593239796 hasConcept C2780482068 @default.
• W2593239796 hasConcept C502942594 @default.
• W2593239796 hasConcept C530470458 @default.
• W2593239796 hasConcept C61238886 @default.
• W2593239796 hasConcept C71924100 @default.
• W2593239796 hasConcept C84606932 @default.
• W2593239796 hasConceptScore W2593239796C121608353 @default.
• W2593239796 hasConceptScore W2593239796C126322002 @default.
• W2593239796 hasConceptScore W2593239796C143998085 @default.
• W2593239796 hasConceptScore W2593239796C172313692 @default.
• W2593239796 hasConceptScore W2593239796C2775930923 @default.
• W2593239796 hasConceptScore W2593239796C2776166826 @default.
• W2593239796 hasConceptScore W2593239796C2778504769 @default.
• W2593239796 hasConceptScore W2593239796C2779013556 @default.
• W2593239796 hasConceptScore W2593239796C2780482068 @default.
• W2593239796 hasConceptScore W2593239796C502942594 @default.
• W2593239796 hasConceptScore W2593239796C530470458 @default.
• W2593239796 hasConceptScore W2593239796C61238886 @default.
• W2593239796 hasConceptScore W2593239796C71924100 @default.
• W2593239796 hasConceptScore W2593239796C84606932 @default.
• W2593239796 hasLocation W25932397961 @default.
• W2593239796 hasOpenAccess W2593239796 @default.
• W2593239796 hasPrimaryLocation W25932397961 @default.
• W2593239796 hasRelatedWork W10138567 @default.
• W2593239796 hasRelatedWork W12242190 @default.
• W2593239796 hasRelatedWork W14333088 @default.
• W2593239796 hasRelatedWork W15116175 @default.
• W2593239796 hasRelatedWork W17379279 @default.
• W2593239796 hasRelatedWork W20667999 @default.
• W2593239796 hasRelatedWork W2083469 @default.
• W2593239796 hasRelatedWork W4185548 @default.
• W2593239796 hasRelatedWork W718895 @default.
• W2593239796 hasRelatedWork W7207526 @default.
• W2593239796 isParatext "false" @default.
• W2593239796 isRetracted "false" @default.
• W2593239796 magId "2593239796" @default.
• W2593239796 workType "article" @default.